Evaluation of PKU Sphere in Maternal PKU

Last updated: May 14, 2025
Sponsor: Vitaflo International, Ltd
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

PKU sphere

Clinical Study ID

NCT04224142
MCT-GMP-2018-08-14
256857
19/NW/0167
  • Ages > 16
  • Female

Study Summary

This observational study aims to recruit females, aged 16 years and over, with phenylketonuria (PKU) or hyperphenylalaninemia (hyperphe) following dietary management advice pre-conception and/or during pregnancy, who are willing to take PKU sphere as part of their dietarty management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of phenylketonuria (PKU) or hyperphenylalaninemia (hyperphe) whichrequires dietary management during pre-conception and/or pregnancy.

  • Aged 16 years and above.

  • Following dietary management advice pre-conceptually and/or during pregnancy, aimingfor phenylalanine levels of 120-250µmol/L.

  • Prior positive PKU sphere taste test completed as part of routine care.

  • Chosen to take part or full requirement of protein substitute as PKU spherepre-conceptually and/or during pregnancy.

  • Willingly given, written, informed consent from patient.

  • Participant is, in the opinion of the investigator, able to participate and cancomply with the study protocol.

Exclusion

Exclusion Criteria:

  • Conception of pregnancy without commencement of phe-restricted diet and bloodphenylalanine not maintained within target range by 10 weeks' gestation.

  • Patients with known soya, milk or fish allergies / intolerance.

  • Intake of pegvaliase or large neutral amino acids within 30 days prior to screeningvisit.

  • Patients who are currently participating in, plan to participate in, or haveparticipated in an interventional investigational drug, food or medical device trialwithin 30 days prior to screening visit.

Study Design

Total Participants: 12
Treatment Group(s): 1
Primary Treatment: PKU sphere
Phase:
Study Start date:
July 29, 2019
Estimated Completion Date:
March 14, 2025

Study Description

The aim of this study is to observe dietary management and metabolic control in women taking PKU sphere pre-conceptually and/or during pregnancy. To do this the following data points will be captured:

  • Blood spot phenylalanine and tyrosine levels to measure metabolic control

  • Changes to dietary management and any adaptations arising from incorporating PKU Sphere

  • Compliance/adherence of patients to their recommended amount of protein substitute prescription.

  • Tolerance of PKU sphere with respect to gastrointestinal (GI) symptoms and pregnancy associated nausea and vomiting.

  • Acceptability of concurrent protein substitute(s) (if applicable).

  • Nutritional status and weight management.

  • Routine standard of care data on the final pregnancy outcome and postpartum.

Connect with a study center

  • Royal Victoria Hospital

    Belfast,
    United Kingdom

    Site Not Available

  • University Hospital of Wales

    Cardiff,
    United Kingdom

    Site Not Available

  • NHS Greater Glasgow and Clyde

    Glasgow,
    United Kingdom

    Site Not Available

  • University College London Hospitals NHS Foundation Trust

    London,
    United Kingdom

    Site Not Available

  • Salford Royal Hospital

    Salford,
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.